ANIP insider buying and SEC filings, explained
Ani Pharmaceuticals Inc. · CIK 1023024
Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov
Insider activity in the last 12 months
Bought
$0
Insiders who bought
0
Sold (not marked 10b5-1)
$9.6M
Planned sales (10b5-1)
$6.1M
Insider purchases and sales, last 12 months
| Traded | Type | What was filed | Source |
|---|---|---|---|
| Oct 29, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 2,850 shares at about $72.87 ($208K), marked as a 10b5-1 plan trade. Holdings down 2% to 166,143 shares. | SEC filing Filed Oct 30, 2026, 4:36 PM ET |
| Oct 15, 2026 | Planned (10b5-1) | Nikhil Lalwani (CEO and Director) sold 5,400 shares at about $71.89 ($388K), marked as a 10b5-1 plan trade. Holdings down 2% to 333,689 shares. | SEC filing Filed Oct 16, 2026, 6:50 PM ET |
| Oct 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $73.59 ($37K), marked as a 10b5-1 plan trade. Holdings down 1% to 73,424 shares. | SEC filing Filed Oct 13, 2026, 8:47 PM ET |
| Sep 29, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 2,850 shares at about $73.00 ($208K), marked as a 10b5-1 plan trade. Holdings down 2% to 168,993 shares. | SEC filing Filed Sep 30, 2026 |
| Sep 15, 2026 | Planned (10b5-1) | Nikhil Lalwani (CEO and Director) sold 5,400 shares at $71.00 ($383K), marked as a 10b5-1 plan trade. Holdings down 2% to 339,089 shares. | SEC filing Filed Sep 16, 2026 |
| Sep 14, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $70.79 ($35K), marked as a 10b5-1 plan trade. Holdings down 1% to 73,924 shares. | SEC filing Filed Sep 14, 2026 |
| Sep 11, 2026 | Planned (10b5-1) | Jeanne Thoma (Director) sold 1,000 shares at $71.53 ($72K), marked as a 10b5-1 plan trade. Holdings down 4% to 26,762 shares. | SEC filing Filed Sep 14, 2026 |
| Aug 31, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 2,850 shares at about $72.80 ($207K), marked as a 10b5-1 plan trade. Holdings down 2% to 171,843 shares. | SEC filing Filed Sep 1, 2026 |
| Aug 25, 2026 | Planned (10b5-1) | Nikhil Lalwani (CEO and Director) sold 5,400 shares at about $74.30 ($401K), marked as a 10b5-1 plan trade. Holdings down 2% to 344,489 shares. | SEC filing Filed Aug 26, 2026 |
| Aug 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $75.48 ($38K), marked as a 10b5-1 plan trade. Holdings down 1% to 74,424 shares. | SEC filing Filed Aug 13, 2026 |
| Aug 10, 2026 | Sale | Ori Gutwerg (SVP, Generics) sold 3,162 shares at $77.00 ($243K). Holdings down 4% to 75,534 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Aug 11, 2026 |
| Jul 29, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 2,850 shares at about $81.36 ($232K), marked as a 10b5-1 plan trade. Holdings down 2% to 174,693 shares. | SEC filing Filed Jul 30, 2026 |
| Jul 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $81.84 ($41K), marked as a 10b5-1 plan trade. Holdings down 1% to 77,390 shares. | SEC filing Filed Jul 14, 2026 |
| Jul 2, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 3,313 shares at $86.00 ($285K), marked as a 10b5-1 plan trade. Holdings down 2% to 177,543 shares. | SEC filing Filed Jul 6, 2026 |
| Jun 29, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 2,850 shares at about $84.12 ($240K), marked as a 10b5-1 plan trade. Holdings down 2% to 177,543 shares. | SEC filing Filed Jun 30, 2026 |
| Jun 12, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $82.03 ($41K), marked as a 10b5-1 plan trade. Holdings down 1% to 77,890 shares. | SEC filing Filed Jun 15, 2026 |
| Jun 8, 2026 | Planned (10b5-1) | Thomas Haughey (Director) sold 2,000 shares at $80.88 ($162K), marked as a 10b5-1 plan trade. Holdings down 5% to 38,878 shares. | SEC filing Filed Jun 10, 2026 |
| Jun 5, 2026 | Planned (10b5-1) | Stephen P. Carey (CFO) sold 3,312 shares at $80.00 ($265K), marked as a 10b5-1 plan trade. Holdings down 2% to 180,393 shares. | SEC filing Filed Jun 9, 2026 |
| May 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $78.16 ($39K), marked as a 10b5-1 plan trade. Holdings down 1% to 78,390 shares. | SEC filing Filed May 13, 2026 |
| May 12, 2026 | Sale | Ori Gutwerg (SVP, Generics) sold 2,772 shares at $79.50 ($220K). Holdings down 3% to 78,696 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 12, 2026 | Sale | Thomas Andrew Rowland (SVP, Head - Established Brands) sold 459 shares at $79.21 ($36K). Holdings down 1% to 38,271 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 11, 2026 | Sale | Nikhil Lalwani (CEO and Director) sold 55,000 shares at about $77.57 ($4.3M). Holdings down 14% to 349,889 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| May 11–13, 2026 | Sale | Patrick D Walsh (Director) sold 13,973 shares between May 11 and May 13 at about $80.66 ($1.1M). Holdings down 27% to 38,432 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed May 13, 2026 |
| Apr 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $77.95 ($39K), marked as a 10b5-1 plan trade. Holdings down 1% to 78,890 shares. | SEC filing Filed Apr 13, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $72.62 ($36K), marked as a 10b5-1 plan trade. Holdings down 1% to 79,390 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 13, 2026 | Planned (10b5-1) | Christopher Mutz (Head of Rare Disease) sold 3,162 shares at about $71.64 ($227K), marked as a 10b5-1 plan trade. Holdings down 3% to 91,309 shares. | SEC filing Filed Mar 13, 2026 |
| Mar 11, 2026 | Sale | Thomas Andrew Rowland (SVP, Head - Established Brands) sold 4,772 shares at $74.91 ($357K). Holdings down 11% to 38,730 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 13, 2026 |
| Mar 6–9, 2026 | Planned (10b5-1) | Krista Davis (SVP, Chief HR Officer) sold 6,572 shares between Mar 6 and Mar 9 at about $74.33 ($488K), marked as a 10b5-1 plan trade. Holdings down 11% to 51,946 shares. | SEC filing Filed Mar 10, 2026 |
| Mar 6–9, 2026 | Planned (10b5-1) | Christopher Mutz (Head of Rare Disease) sold 5,723 shares between Mar 6 and Mar 9 at about $74.19 ($425K), marked as a 10b5-1 plan trade. Holdings down 6% to 94,471 shares. | SEC filing Filed Mar 10, 2026 |
| Mar 5, 2026 | Sale | Stephen P. Carey (CFO) sold 7,312 shares at about $75.50 ($552K). Holdings down 4% to 185,543 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 5, 2026 |
| Mar 3, 2026 | Sale | Ori Gutwerg (SVP, Generics) sold 2,060 shares at $76.50 ($158K). Holdings down 2% to 84,782 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 4, 2026 |
| Mar 2, 2026 | Planned (10b5-1) | Christopher Mutz (Head of Rare Disease) sold 417 shares at $74.00 ($31K), marked as a 10b5-1 plan trade. Holdings down <1% to 103,508 shares. | SEC filing Filed Mar 4, 2026 |
| Mar 3, 2026 | Sale | Patrick D Walsh (Director) sold 6,000 shares at $74.23 ($445K). Holdings down 10% to 52,405 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Mar 3, 2026 |
| Feb 20, 2026 | Planned (10b5-1) | Christopher Mutz (Head of Rare Disease) sold 5,323 shares at about $78.02 ($415K), marked as a 10b5-1 plan trade. Holdings down 6% to 84,840 shares. | SEC filing Filed Feb 23, 2026 |
| Feb 19–20, 2026 | Planned (10b5-1) | Krista Davis (SVP, Chief HR Officer) sold 3,814 shares between Feb 19 and Feb 20 at about $77.74 ($296K), marked as a 10b5-1 plan trade. Holdings down 7% to 49,263 shares. | SEC filing Filed Feb 23, 2026 |
| Feb 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $76.80 ($38K), marked as a 10b5-1 plan trade. Holdings down 1% to 69,329 shares. | SEC filing Filed Feb 17, 2026 |
| Feb 12, 2026 | Planned (10b5-1) | Christopher Mutz (Head of Rare Disease) sold 7,032 shares at about $76.55 ($538K), marked as a 10b5-1 plan trade. Holdings down 7% to 92,566 shares. | SEC filing Filed Feb 17, 2026 |
| Jan 13, 2026 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 500 shares at $84.33 ($42K), marked as a 10b5-1 plan trade. Holdings down 1% to 74,374 shares. | SEC filing Filed Jan 14, 2026 |
| Dec 18, 2025 | Planned (10b5-1) | Krista Davis (SVP, Chief HR Officer) sold 1,622 shares at $82.40 ($134K), marked as a 10b5-1 plan trade. Holdings down 3% to 58,564 shares. | SEC filing Filed Dec 19, 2025 |
| Dec 12, 2025 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 400 shares at $82.32 ($33K), marked as a 10b5-1 plan trade. Holdings down 1% to 74,874 shares. | SEC filing Filed Dec 12, 2025 |
| Dec 5, 2025 | Sale | Renee P. Tannenbaum (Director) sold 1,800 shares at about $81.15 ($146K). Holdings down 7% to 25,157 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Dec 9, 2025 |
| Nov 13, 2025 | Sale | Patrick D Walsh (Director) sold 8,643 shares at about $86.88 ($751K). Holdings down 12% to 61,405 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 17, 2025 |
| Nov 13, 2025 | Planned (10b5-1) | Meredith Cook (Sr. VP, General Counsel & Sec.) sold 400 shares at $87.27 ($35K), marked as a 10b5-1 plan trade. Holdings down 1% to 75,274 shares. | SEC filing Filed Nov 14, 2025 |
| Nov 12–13, 2025 | Sale | Chad Gassert (SVP - Corp. Dev. & Strategy) sold 14,736 shares indirectly (by entity) between Nov 12, 2025 and Nov 13, 2025 at about $89.06 ($1.3M). Holdings by entity down 9% to 158,490 shares. Not marked as a 10b5-1 plan trade. | SEC filing Filed Nov 14, 2025 |
41 routine transactions (such as grants, option exercises or tax withholding) are not listed.
Cluster buys
No cluster buys in the last 12 months.
Red flags
No red flags in the last 12 months.
Key events
No key events in the last 12 months.
8-K filings, last 12 months
No 8-K filings in the last 12 months.
Red flags are objective triggers only: the item or form filed, never an opinion.
Follow ANIP in the Insider Ledger app
Get the appA plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.